DIDRONEL
LOE Approachingetidronate disodium
NDAINJECTIONINJECTABLE
Approved
Apr 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 16h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIDRONEL (etidronate disodium) is a bisphosphonate administered by injection for the treatment of metabolic bone disorders, including heterotopic ossification and Paget's disease. It works by inhibiting bone resorption and reducing abnormal bone turnover. The drug has been in clinical use since 1987 and represents an older generation bisphosphonate therapy.
LOE Approaching
As LOE approaches, the brand team is likely consolidating to focus on niche indications and lifecycle extension strategies rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DIDRONEL offers limited growth trajectory as the product approaches LOE with minimal linked job openings and declining commercial momentum. Positions are best suited for professionals interested in specialty market management, niche indication expertise, or transition-phase portfolio management rather than high-growth commercialization.
Brand Manager (Specialty/Niche)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.